NUPLAZID PRICING AND DISTRIBUTION FACT SHEET



Overview ¹	
Brand name	NUPLAZID®
Generic name	Pimavanserin
National drug codes (NDCs)	NUPLAZID 34 mg capsules (bottle of 30): NDC 63090-340-30 NUPLAZID 10 mg tablets (bottle of 30): NDC 63090-100-30
Indication and usage	NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Dosage and administration	The recommended dose of NUPLAZID is 34 mg taken orally once daily, without titration. NUPLAZID can be taken with or without food. NUPLAZID capsules can be taken whole, or opened and the entire contents sprinkled over a tablespoon (15 mL) of applesauce, yogurt, pudding, or a liquid nutritional supplement. Consume the drug/food mixture immediately without chewing; do not store for future use. Coadministration with strong CYP3A4 inhibitors increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily. Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.
Manufacturer	Acadia Pharmaceuticals Inc.
Distribution	
Specialty distributors	Eligible government, long-term care, and hospital inpatient pharmacies may order NUPLAZID directly from: • ASD Healthcare: • Cardinal Health Cencora 1-844-794-7276 1-800-746-6273 • McKesson Plasma and Biologics 1-800-710-6100 1-877-625-2566
Group purchasing organizations	MHA 1-800-642-3020
Specialty pharmacy network	 Accredo Specialty Pharmacy 1-877-222-7336
Price and support	
Wholesale acquisition cost	\$4,995.00 for 30-count bottle (1-month supply) effective October 1, 2023
Support program	Acadia Connect® provides patient access support, including navigating insurance, managing cost, and filling their prescription. Acadia Connect support hotline: 1-844-737-2223 Acadia Connect LTC support hotline: 1-877-889-0739

Important Safety Information

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

- · Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
- NUPLAZID is not approved for the treatment of patients with dementia who experience psychosis unless their hallucinations and delusions are related to Parkinson's disease.

Important Safety Information (cont.)

Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.

Warnings and Precautions: QT Interval Prolongation

- NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval (e.g., Class 1A antiarrhythmics, Class 3 antiarrhythmics, certain antipsychotics or antibiotics).
- NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.

Adverse Reactions: The adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).

Drug Interactions:

- Coadministration with strong CYP3A4 inhibitors increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as
 one tablet once daily.
- Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.

Please read the full Prescribing Information, including Boxed WARNING, also available at NUPLAZIDhcp.com.





